SCHEMBL8486754

SCHEMBL8486754

COC(=O)C(C)c1ccc2cccccc1-2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
PTGS2 P35354 2/20 0.44
PTGS1 P23219 1/20 0.44
FGFR1 P11362 1/20 0.43
SRC P12931 1/20 0.43
FGFR2 P21802 1/20 0.43
FGFR4 P22455 1/20 0.43
FGFR3 P22607 1/20 0.43
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
ALDH1A1 P00352 1/20 0.41
THRB P10828 1/20 0.41
HSD17B10 Q99714 1/20 0.41
EGFR P00533 1/20 0.41
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KLK7 P49862 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10710439 0.95 KMT2A (0.46) KMT2APTGS2PTGS1FGFR1SRC
SCHEMBL30677890 0.87 ABL1 (0.44) KMT2APTGS2PTGS1ALDH1A1THRB
SCHEMBL28518787 0.84 PTGS1 (0.46) KMT2APTGS2PTGS1FGFR1SRC
SCHEMBL8479916 0.82 PTGS2 (0.58) KMT2APTGS2PTGS1CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6981180 0.80 PTGS1 (0.43) KMT2APTGS2PTGS1FGFR1SRC
SCHEMBL2392888 0.79 LMNA (0.46) KMT2ACYP2C9CYP2C19ALDH1A1PPARA
SCHEMBL1901275 0.78 KMT2A (0.46) KMT2AFGFR1SRCFGFR2FGFR4
SCHEMBL10914468 0.78 PPARA (0.42) KMT2APTGS2ALDH1A1PPARAPPARG
SCHEMBL4827831 0.77 PTGS2 (0.67) KMT2APTGS2PTGS1CYP2C9CYP2C19
SCHEMBL2393839 0.77 PTGS2 (0.56) KMT2APTGS2PTGS1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5990158-A EXTRACELLULAR MATRIX METALLOPROTEINASES INHIBITORS; ORAL ADMINISTRATION; BIOAVAILABILITY; E.G.,N-(2-(2'-(5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYLENE-OXY-2'-OXO-ETHYL)-5 -(4-METH-OXYPHENYL)OXY)PENTANOYL)PHENYLALANINE N-METHYLAMIDE KOTOBUKI SEIYAKU CO., LTD. (JP) 1999-11-23 US disclosed